40,210 Shares in Cryoport, Inc. (NASDAQ:CYRX) Acquired by B. Metzler seel. Sohn & Co. Holding AG

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Cryoport, Inc. (NASDAQ:CYRX) during the third quarter, HoldingsChannel.com reports. The fund purchased 40,210 shares of the company’s stock, valued at approximately $326,000.

A number of other institutional investors also recently bought and sold shares of CYRX. Comerica Bank raised its position in Cryoport by 73.0% during the 1st quarter. Comerica Bank now owns 3,481 shares of the company’s stock worth $62,000 after buying an additional 1,469 shares during the last quarter. Quest Partners LLC increased its position in Cryoport by 1,083,000.0% during the 2nd quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock worth $75,000 after purchasing an additional 10,830 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of Cryoport in the 2nd quarter valued at approximately $92,000. Lazard Asset Management LLC boosted its stake in shares of Cryoport by 294.3% in the first quarter. Lazard Asset Management LLC now owns 5,378 shares of the company’s stock valued at $95,000 after buying an additional 4,014 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in Cryoport by 9.5% during the second quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock worth $122,000 after acquiring an additional 1,534 shares during the period. 92.90% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Cryoport

In other news, CEO Jerrell Shelton sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $6.78, for a total value of $339,000.00. Following the sale, the chief executive officer now directly owns 712,747 shares in the company, valued at approximately $4,832,424.66. This represents a 6.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 10.10% of the company’s stock.

Cryoport Price Performance

Shares of NASDAQ:CYRX opened at $6.56 on Monday. The stock has a market capitalization of $324.26 million, a P/E ratio of -1.94 and a beta of 1.63. The business has a 50-day moving average of $7.50 and a two-hundred day moving average of $8.58. Cryoport, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $20.10. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Cryoport announced that its Board of Directors has approved a share repurchase program on Tuesday, August 6th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 49.1% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several brokerages have commented on CYRX. UBS Group boosted their target price on shares of Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday, October 18th. Needham & Company LLC cut their price objective on Cryoport from $18.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Roth Mkm lowered their target price on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th. B. Riley upgraded Cryoport from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $19.00 to $15.00 in a research report on Wednesday, July 31st. Finally, Jefferies Financial Group downgraded shares of Cryoport from a “buy” rating to a “hold” rating and reduced their price objective for the company from $20.00 to $8.00 in a research note on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.50.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.